Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)


NCTID NCT02599922 (View at clinicaltrials.gov)
Description
Development Status Inactive
Indication Achromatopsia
Disease Ontology Term DOID:0110008
Compound Name AGTC-401
Compound Description rAAV2tYF-PR1.7-hCNGB3
Sponsor Beacon Therapeutics
Funder Type Industry
Recruitment Status
Active not recruiting
Enrollment Count 32
Results Posted Not Available

Therapy Information


Target Gene/Variant CNGB3
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Subretinal
Drug Product Type Viral vector
Target Tissue/Cell Cone cells
Delivery System Viral transduction
Vector Type AAV2tYF
Editor Type none
Dose 1 2E11 vg/ml
Dose 2 4E10 vg/ml
Dose 3 1.2E11 vg/ml
Dose 4 3.6E11 vg/ml
Dose 5 1.1E12 vg/ml; Dose 6: 3.2E12

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2015-11-05
Completion Date 2026-07
Last Update 2022-07-22

Participation Criteria


Eligible Age >=4 Years
Standard Ages Child, Adult, Older adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 8
Locations United States

Regulatory Information


Has US IND True
FDA Designations
Recent Updates Development discontinued by Sponsor

Resources/Links